Articles published by Antibe Therapeutics Inc.
Antibe Announces Appointment of Receiver
April 24, 2024
Antibe Provides Update on CCAA Proceedings
April 19, 2024
Antibe Announces TSX Delisting Review
April 16, 2024
Antibe Reports Q3 2024 Interim Financial and Operating Results
February 14, 2024
Antibe Extends Early Warrant Exercise Incentive Program
February 01, 2024
Antibe Announces Early Warrant Exercise Incentive Program
December 29, 2023
Antibe Therapeutics Announces Amendment to Warrant Terms
December 12, 2023
Antibe Reports Q2 2024 Interim Financial and Operating Results
November 13, 2023
Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation
November 01, 2023
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
September 28, 2023
Antibe Announces Results of 2023 Annual Meeting
September 08, 2023
Antibe Reports Q1 2024 Interim Financial and Operating Results
August 14, 2023
Antibe Provides April 2023 Corporate Update
April 11, 2023
Antibe Reports Q3 2023 Interim Financial and Operating Results
February 15, 2023
Antibe Reports Q2 2023 Interim Financial and Operating Results
November 15, 2022
Antibe Provides Development Update for Otenaproxesul
October 12, 2022
Antibe Announces Results of 2022 Annual Meeting
September 09, 2022
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
September 06, 2022
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.